Beckman, Recognizing Inverness' Bid for Biosite, Extends Own Offer Deadline | GenomeWeb
NEW YORK (GenomeWeb News) — Beckman Coulter today said it has extended its offer to buy Biosite to May 2, which the day that a counteroffer by Inverness Medical Innovations runs out.
 
Late last week, Biosite told Beckman Coulter that it “currently intends” to accept a rival offer from Inverness, which proposes to buy the company for $90 a share. Beckman’s original offer, made in March, was for $85 a share.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: intellectual property landscape of CRISPR genome editing, and more.

A researcher has been convicted of conspiring to steal genetically engineered rice, Reuters reports.

Harvard Medical School's George Church says a woolly mammoth-elephant hybrid is only a few years away, according to the New Scientist.

Intel is ending its sponsorship of the International Science and Engineering Fair, the New York Times reports.